Astrazeneca plc, of London, said the European Commission approved Faslodex (fulvestrant) for the treatment of estrogen receptor (HR)-positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy. Approval was based on data from the phase III FALCON study, which demonstrated the superiority of Faslodex 500 mg over anastrozole 1 mg as a first-line treatment for postmenopausal women with locally advanced or HR-positive metastatic breast cancer who had not received prior hormone-based therapy. Faslodex first gained approval in 2002.